BIOX Hedge Fund Ownership (Q1 2026)

Q: Is it too late to buy Bioceres Crop Solutions Corp (BIOX) following the 2026 Q2 hedge fund 13F filings?

As of today, BIOX has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the SPY sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), BIOX gained +28.5% vs +4.0% for SPY. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Bioceres Crop Solutions Corp (BIOX)

30 + Investors. Track Smart Money conviction in BIOX. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — BIOX

Based on 31 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q

For 1 consecutive quarter, more hedge funds reduced or closed their BIOX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

🔻

Below peak — only 60% of 3.0Y high

60% of all-time peak

Only 31 funds hold BIOX today versus a peak of 52 funds at 2024 Q1 — just 60% of the maximum. Low institutional ownership can mean the stock is out of favor, but it also means there's a large pool of potential buyers if sentiment turns.

📉

Outflows — 16% fewer funds vs a year ago

fund count last 6Q

6 fewer hedge funds hold BIOX compared to a year ago (-16% decline). When institutions consistently reduce their exposure, it's worth exploring the underlying fundamental reasons driving them away.

🟠

More sellers than buyers — 45% buying

13 buying16 selling

Last quarter: 16 funds reduced or exited vs 13 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

⚠️

Fewer new buyers each quarter (-6 vs last Q)

new funds entering per quarter

Funds opening this position for the first time: 6 → 10 → 10 → 4. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.

🔒

52% of holders stayed for 2+ years

■ 52% conviction (2yr+) ■ 26% medium ■ 23% new

16 out of 31 hedge funds have held BIOX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

💎

Buying through price weakness — shares -32%, value -77%

Value

-77%

-32%

Last quarter: funds added -32% more shares while total portfolio value only changed -77%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.

➡️

Steady discovery — ~4 new funds/quarter

4 → 6 → 10 → 10 → 4 new funds/Q

New funds entering each quarter: 6 → 10 → 10 → 4. Consistent flow of new institutional buyers without clear acceleration or slowdown.

🏛️

Veteran-anchored — 61% veterans vs 23% newcomers

■ 61% veterans ■ 16% 1-2yr ■ 23% new

Entry-cohort mix of 31 holders: 19 (61%) are 2+ year veterans, 5 entered 1–2 years ago, and 7 (23%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

📋

Smaller funds dominant — 12% AUM from top-100

12% from top-100 AUM funds

11 of 30 holders rank in the top 100 by AUM, but together hold only 12% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

1.8

out of 10

Low Exit Risk

Exit risk score 1.8/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	30	38	-21.05%
13F Shares	9M	14M	-32.42%
Total Value	$4M	$18M	-77.13%
New Positions	3	10	-7
Increased Positions	9	7	+2
Closed Positions	11	9	+2
Reduced Positions	5	11	-6
Total Calls	1	1	-
Total Puts	0	0	-
PUT/CALL Ratio	0.0	0.0	Bullish

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

-21.05%

13F Shares

14M

-32.42%

Total Value

$4M

$18M

-77.13%

New Positions

-7

Increased Positions

Closed Positions

Reduced Positions

-6

Total Calls

Total Puts

PUT/CALL Ratio

0.0

Bullish

Institutional Holders (2026 Q2)

30 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in BIOX. Verified SEC 13F-HR filings.

QUARTER:

2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 BIOX holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Solel Partners LP	0.27%	4,579,364	$1.6M
2	Ardsley Advisory Partners LP	0.02%	475,000	$166K
3	Long Focus Capital Management, LLC	0.01%	829,748	$290K
4	Ping Capital Management, INC.	0.00%	55,000	$19K
5	Ping Capital Management, INC.	0.00%	30,000	$11K
6	MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	0.00%	1,406,223	$492K
7	MJT & Associates Financial Advisory Group, Inc.	0.00%	1,487	—
8	Tower Research Capital LLC (TRC)	0.00%	9,547	$3K
9	PNC Financial Services Group, INC.	0.00%	133,000	$47K
10	J.Safra Asset Management Corp	0.00%	1,400	—
11	UBS Group AG	0.00%	408,276	$143K
12	Stifel Financial Corp	0.00%	29,588	$10K
13	Two Sigma Investments, LP	0.00%	30,026	$11K
14	Group One Trading LLC	0.00%	15,257	$5K
15	Citadel Advisors LLC	0.00%	169,500	$59K
16	Susquehanna International Group, LLP	0.00%	212,930	$75K
17	EFG International AG	0.00%	750	—
18	Goldman Sachs Group Inc	0.00%	129,445	$45K
19	SBI Securities Co., Ltd.	0.00%	279	—
20	Harbour Investments, INC.	0.00%	352	—
21	Jane Street Group, LLC	0.00%	36,268	$13K
22	Osaic Holdings, INC.	0.00%	1,205	—
23	Citadel Advisors LLC	0.00%	11,600	$4K
24	Morgan Stanley	0.00%	18,014	$6K
25	Allworth Financial LP	0.00%	211	—

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Bioceres Crop Solutions Corp (BIOX)

What does the Smart Money Trend signal show for BIOX?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their BIOX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for BIOX?

More sellers than buyers — 45% buying: Last quarter: 16 funds reduced or exited vs 13 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

What is the fund quality score for BIOX holders?

Smaller funds dominant — 12% AUM from top-100: 11 of 30 holders rank in the top 100 by AUM, but together hold only 12% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held BIOX?

52% of holders stayed for 2+ years: 16 out of 31 hedge funds have held BIOX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Bioceres Crop Solutions Corp (BIOX) following the 2026 Q2 hedge fund 13F filings?

As of today, BIOX has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the SPY sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), BIOX has gained +28.5% vs +4.0% for SPY. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Bioceres Crop Solutions Corp (BIOX)

Smart Money Signals — BIOX

Selling streak — 1 quarter in a row

Below peak — only 60% of 3.0Y high

Outflows — 16% fewer funds vs a year ago

More sellers than buyers — 45% buying

Fewer new buyers each quarter (-6 vs last Q)

52% of holders stayed for 2+ years

Buying through price weakness — shares -32%, value -77%

Steady discovery — ~4 new funds/quarter

Veteran-anchored — 61% veterans vs 23% newcomers

Smaller funds dominant — 12% AUM from top-100

Institutional Sentiment Summary — BIOX

Hedge Fund Ownership: BIOX

Market Analysis: BIOX

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: BIOX

Is It Too Late to Buy Bioceres Crop Solutions Corp (BIOX) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: BIOX

Statistics: BIOX

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Bioceres Crop Solutions Corp (BIOX)

Welcome to 13Foresight!